top of page
  • Facebook
  • Twitter
  • Instagram
Cotes Headshot.jpg

Robert Cotes, MD
Professor
Emory University School of Medicine

Clozapine Monitoring Post REMS
Saturday, February 13, 2027
11:15 AM - 12:15 PM

Robert O. Cotes, MD, is a Professor at Emory University School of Medicine in the Department of Psychiatry and Behavioral Sciences. Dr. Cotes is Chief of Psychiatry at Grady Health System. 

​

 

 

He is the founder and Co-Director of the Clinical & Research Program for Psychosis at Grady Health System, which comprises of three clinical programs: 1) PSTAR, which provides evidence-based, recovery-oriented care for individuals with persistent symptoms of psychosis, specializing in the use of clozapine, and 2) Project ARROW, a coordinated specialty care team for people experiencing prodromal and early psychosis, and 3) Youth and Family TREE, a program for youth and young adults with co-occurring disorders. His research focuses on clozapine, pharmacologic and psychosocial interventions for people with schizophrenia, cardiometabolic side effects of antipsychotic medication, and understanding the potential for digital biomarkers in mental health. He is Editor-In-Chief of Community Mental Health Journal and serves on the NAMI Scientific Advisory Council.
 

Lecture Summary:

This presentation will examine the evolving use of clozapine following the elimination of the Clozapine REMS program and what this change means for clinical practice. The session will review current indications for clozapine, the evidence surrounding clozapine-associated neutropenia, and the timing of greatest hematologic risk. It will also explore practical approaches to monitoring in the post-REMS era, with an emphasis on maintaining patient safety while reducing unnecessary barriers to access for this important treatment.

​Goals and Learning Objectives:

  • Identify the three clinical circumstances in which clozapine is recommended in the APA Practice Guideline for the Treatment of Patients With Schizophrenia.

  • Describe the incidence and timing of clozapine-associated neutropenia, including the period of greatest risk.

  • Evaluate the potential benefits and challenges of hematologic monitoring in the post-REMS era.

​

Disclosures:

Advisory Board : Amani Therapeutics
Grant/Research Support : Boehringer Ingelheim, Bristol Myers Squibb, Newron Pharmaceuticals
Consultant : Boehringer Ingelheim, IQVIA, Syneos Health o/b/o Clozapine Product Manufacturers Group, Saladax Biomedical
Other Financial Benefit : Editorial stipend - Springer

bottom of page